NIH SBIR Phase IIB Strategic Breakthrough Award
Funds United States small businesses commercializing biomedical technologies after an NIH SBIR or STTR Phase II award.
The NIH SBIR Phase IIB Strategic Breakthrough Award is a parent R44 opportunity under NIH small-business funding, with NIMH listed as one of the participating institutes through the catalog refresh. The opportunity is for small businesses that have already received an NIH SBIR or STTR Phase II award and need follow-on non-dilutive support for commercialization. The source says the award bridges the gap between the end of Phase II and commercialization, so this is a later-stage company path rather than a first feasibility grant. Eligibility is limited to United States small business concerns with prior NIH SBIR/STTR Phase II funding. The source page lists the opportunity number PA-27-101 and a closing date of April 5, 2029, but it does not state award amounts, review timing, or a scoring rubric on the captured page.
Biomedical research and commercialization projects that have already completed an NIH SBIR or STTR Phase II award and need Phase IIB support to move toward market adoption.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Sign up free to see where teams trip up